Market Overview - The Chinese medical device market is expected to grow to 1.66 trillion yuan by 2030, with significant growth potential in the medical consumables sector[2] - The global medical device industry reached a total scale of $47.936 billion in 2023, projected to grow to $63.796 billion by 2028[2][7] - By 2025, China's medical device market is anticipated to reach 1.2442 trillion yuan, with a compound annual growth rate (CAGR) of 14.76% from 2017 to 2024[9] Medical Consumables Insights - In 2024, the medical consumables market in China is expected to account for 63.18% of the total medical device market, with a market size of approximately 595 billion yuan[14] - The high-value medical consumables market in China grew from 60.2 billion yuan in 2015 to 250.4 billion yuan in 2024, reflecting a CAGR of 17.2%[15] - The vascular intervention consumables segment is the largest, projected to reach about 91.8 billion yuan in 2024, representing 36.7% of the high-value consumables market[15] Market Performance - The median stock price change for the North Exchange's consumer service sector was -3.78% from March 23 to March 27, 2026, with 7% of companies experiencing an increase[37] - The total market capitalization of the North Exchange consumer service sector decreased from 100.036 billion yuan to 95.322 billion yuan during the same period[41] - The median price-to-earnings (P/E) ratio for the North Exchange consumer service sector fell from 37.5X to 36.5X[40] Company Announcements - Yisheng Mushrooms reported a revenue of 739.29 million yuan for 2025, a year-on-year increase of 19.91%, but a net profit decline of 23.05%[54] - The company plans to distribute a cash dividend of 5.00 yuan per 10 shares, totaling approximately 51.52 million yuan[54]

证券代码：920009 证券简称：丹娜生物 公告编号：2026-013 丹娜（天津）生物科技股份有限公司 关于变更签字注册会计师的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 丹娜（天津）生物科技股份有限公司（以下简称"公司"）分别于 2025 年 4 月 17 日、2025 年 5 月 8 日召开第二届董事会第二十一次会议、2024 年年度股东会， 审议通过《关于续聘会计师事务所的议案》，同意续聘容诚会计师事务所（特殊 普通合伙）（以下简称"容诚事务所"）为公司 2025 年度审计机构，具体内容详见 公司于 2025 年 4 月 17 日在全国中小企业股份转让系统信息披露平台 （https://www.neeq.com.cn/）披露的《续聘 2025 年度会计师事务所的公告》（公 告编号：2025-025）。近日，公司收到容诚事务所出具的《关于变更签字会计师的 说明函》，现将具体情况公告如下： 一、本次签字会计师变更的基本情况 容诚事务所作为公司 2025 年度财务报表和内部控制的审计机构，原 ...

Core Viewpoint - The Beijing Stock Exchange (BSE) has reached a significant milestone with 300 listed companies, marking a 3.7 times increase in company numbers since its inception in November 2021, and a total market capitalization of approximately 900 billion yuan [1][4]. Group 1: Market Growth and Performance - The BSE has shown remarkable growth over four years, with the number of listed companies increasing from 81 to 300 and total market capitalization rising from under 300 billion yuan to around 900 billion yuan [4]. - In 2025, 63% of the 293 companies that reported earnings achieved revenue growth, with three companies experiencing revenue increases exceeding 100% [5]. - The average research and development intensity among the 300 listed companies exceeds 5%, with total fundraising surpassing 60 billion yuan, primarily directed towards R&D and capacity expansion [5]. Group 2: New Listings and Industry Focus - In 2026, 12 new companies were listed on the BSE, with a strong emphasis on high-end equipment, artificial intelligence, new materials, biomedicine, and industrial software [7]. - Over 70% of the new listings are classified as national-level specialized and innovative "little giants," showcasing a focus on cutting-edge technology and niche market leadership [7]. - The first-day stock price increases for new listings predominantly fell within the 100% to 200% range, indicating a robust market response and improved investor confidence [7]. Group 3: Future Outlook and Strategic Recommendations - The increase to 300 listed companies represents not only growth but also a new starting point for the BSE, emphasizing the need for continued reform and optimization of the market ecosystem [9][11]. - Experts suggest that the BSE should enhance its appeal to quality companies and improve market liquidity by potentially introducing an ETF and accelerating the implementation of reform measures [10]. - The BSE aims to differentiate itself by focusing on serving innovative small and medium-sized enterprises, ensuring a sustainable growth trajectory and a supportive market environment [10][11].

Group 1 - The report highlights that AI is progressively reshaping the medical value chain, addressing the widening gap in medical resources by enhancing productivity in drug development and diagnostics [2][12][19] - The global generative AI market in healthcare is projected to reach $22 billion by 2027, with a CAGR of 85% from 2023 to 2027, outpacing other sectors like finance and retail [2][11][28] - Key areas for investment include AI in drug development, medical imaging, assisted diagnosis, personalized treatment, and health management, with a focus on sectors with high technological maturity and clear business models [2][37][50] Group 2 - AI in drug development is expected to significantly reduce research time by approximately 25% and improve clinical trial efficiency by 20-30% through automation [13][43] - The AI medical imaging market is evolving from being an auxiliary tool to a diagnostic partner, with multi-modal models enhancing the ability to process diverse medical data [50][51][60] - The report identifies key companies in the North Exchange, such as Jinbo Bio and Baiying Bio, which are focusing on AI-driven drug development and diagnostics [2][29][31] Group 3 - The report emphasizes the importance of identifying structural opportunities in the healthcare sector, particularly in high-potential areas like AI-assisted drug development and medical imaging [37][38] - The investment landscape is becoming more rational, with a focus on diagnostics and drug development, as evidenced by the increasing number of financing events in these sectors [29][31] - The report outlines the government's supportive policies aimed at promoting AI in healthcare, transitioning from pilot projects to large-scale implementations by 2027 and 2030 [25][28]

证券代码：920009 证券简称：丹娜生物 公告编号：2026-012 丹娜（天津）生物科技股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 投资者关系活动类别 □特定对象调研 □业绩说明会 □媒体采访 □新闻发布会 □分析师会议 □路演活动 √其他 （券商策略会） 二、 投资者关系活动情况 活动时间：2026 年 3 月 5 日 活动地点：上海浦东丽晶酒店 参会单位及人员：申万宏源证券研究所、国泰海通证券、华泰证券、开源证 券、中泰证券、申万宏源证券温州分公司、玖歌投资、汇添富基金、平安财智投 资、青岛四时基金、荣信泰基金、晨鸣基金、前海鸿富、岱熹投资、圆信永丰基 金、朴拙资本、通乾投资、上海京标、昱弘资管、毅远基金（排名不分先后） 上市公司接待人员：公司董事会秘书李浩一 三、 投资者关系活动主要内容 □现场参观 问题三：请介绍一下鲎血细胞的供应情况及替代产品情况。 回答：鲎自 2021 年升级为国家二级保护动物，目前国内市场上暂无增量 鲎血细胞获取渠道。202 ...

证券代码：920009 证券简称：丹娜生物 公告编号：2026-011 丹娜（天津）生物科技股份有限公司 （二）披露标准 根据《北京证券交易所股票上市规则》相关规定，交易的成交金额占上市 公司最近一期经审计净资产的 10%以上，且超过 1,000 万元的应当及时披露。 公司本次以自有闲置资金购买理财产品的合计金额为人民币 8,000 万元， 截至目前，公司使用闲置自有资金购买理财产品未到期余额为 44,600 万元， 占公司最近一期经审计净资产的 86.69%，达到上述披露标准，现予以披露。 1 / 11 二、 本次自有资金购买理财产品情况 关于使用闲置自有资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、 授权使用自有闲置资金购买理财产品情况 （一）审议情况 丹娜（天津）生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日召开了第二届董事会第二十一次会议，2025 年 5 月 8 日召开了 2024 年年 度股东会会议，审议通过了《关于 2025 年 ...

Financial Projections - The company's operating revenue for 2025 is expected to be CNY 241,385,609.40, representing a year-on-year increase of 0.75%[6] - Total profit for the period is projected to be CNY 109,671,070.15, reflecting a growth of 10.62% compared to the previous year[6] - Net profit attributable to shareholders is anticipated to reach CNY 97,120,115.20, marking an 11.39% increase year-on-year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be CNY 77,815,256.10, showing a decline of 3.48%[6] - Basic earnings per share are projected at CNY 1.99, an increase of 8.15% from the previous year[6] Asset and Equity Growth - Total assets at the end of the reporting period are expected to be CNY 745,678,681.96, a growth of 43.55% from the beginning of the period[6] - Shareholders' equity is projected to be CNY 677,078,904.40, reflecting a year-on-year increase of 46.03%[6] - The company issued shares to unspecified qualified investors, which contributed to the increase in total assets and equity[7] Strategic Initiatives - The company plans to expand its user base and enhance market marketing efforts to counter macroeconomic challenges, contributing to revenue growth[7] - Other income increased by 174.58% due to government support funds, significantly impacting total profit growth[7]

证券代码：920009 证券简称：丹娜生物 公告编号：2026-009 丹娜（天津）生物科技股份有限公司 关于使用闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、 授权委托理财情况 （一）审议情况 2025 年 12 月 3 日，公司第二届董事会第二十七次会议审议通过了《关于 使用闲置募集资金进行现金管理的议案》，同意公司使用不超过人民币 11,000 万元的闲置募集资金进行现金管理。使用闲置募集资金进行现金管理的品种应 满足安全性高、流动性好、可以保障投资本金安全等要求，主要为结构性存款、 大额存单、通知存款等本金保障型产品，且购买的产品不作抵押，不用作其他 用途，不会影响募集资金投资计划正常进行。 具体内容详见公司 2025 年 12 月 4 日在在北京证券交易所指定信息披露 平台（www.bse.cn）披露的《关于使用闲置募集资金进行现金管理的公告》（公 告编号：2025-130）。 （二）披露标准 根据《北京证券交易所股票上市规则》相关规定，交易的成交金额 ...

证券代码：920009 证券简称：丹娜生物 公告编号：2026-008 关于使用闲置自有资金购买理财产品的进展公告 丹娜（天津）生物科技股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、 授权使用自有闲置资金购买理财产品情况 （一）审议情况 丹娜（天津）生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日召开了第二届董事会第二十一次会议，2025 年 5 月 8 日召开了 2024 年年 度股东大会会议，审议通过了《关于 2025 年综合授信及使用自有闲置资金购 买理财产品的议案》，同意公司及子公司使用自有闲置资金单笔金额不超过 2 亿元人民币、年度累计总额不超过 60 亿元人民币用于购买理财产品、大额存 单业务等对外投资事项，在授权额度范围内资金可以循环使用。使用自有资金 购买理财产品事项授权期限自 2024 年度股东大会审议通过之日起至 2025 年 度股东大会结束之日止有效，在上述审议通过的额度及授权期内，授权公司董 事长、总经理、财务总监共同决定并办理使用自 ...

Core Insights - Dana Biological (920009) was listed on the Longhu List on January 26, 2026, due to a turnover rate of 36.90% and a trading volume of 2.6571 million shares, amounting to a transaction value of 231 million yuan [1][2]. Trading Activity - The top buying seat was Guosen Securities Co., Ltd. Hangzhou Wenyixi Road Securities Business Department, with a purchase amount of approximately 5.76 million yuan [2]. - The top selling seat was Guosen Securities Co., Ltd. Guangxi Branch, with a selling amount of approximately 6.97 million yuan [2]. - Other notable buying seats included Dongwu Securities Co., Ltd. Shanghai Xizang South Road Securities Business Department (approximately 3.15 million yuan) and Dongfang Caifu Securities Co., Ltd. Lhasa Tuanjie Road First Securities Business Department (approximately 2.86 million yuan) [2].